PURE Bioscience to Present at 6th Annual LD MICRO Conference
2013年11月25日 - 10:30PM
Marketwired
PURE Bioscience to Present at 6th Annual LD MICRO Conference
SAN DIEGO, CA--(Marketwired - Nov 25, 2013) - PURE Bioscience,
Inc. (OTCQB: PURE), creator of the patented silver dihydrogen
citrate (SDC) antimicrobial, today announced that Peter C. Wulff,
CFO & COO, will present at the Sixth Annual LD MICRO Conference
on Thursday, December 5th, at 1:00 PST, at the Luxe Hotel Sunset
Boulevard in Los Angeles.
Mr. Wulff will discuss the Company's outlook and the progress of
the efforts of the new management team to establish PURE's SDC
technology as a novel and proprietary food safety solution. The
presentation will be webcast live and slides may be accessed on the
Company's website, http://www.purebio.com/about/investor_relations.
The presentation will be archived for 90 days.
About LD MICRO
LD MICRO (http://www.ldmicro.com) is a by-invitation only
newsletter firm that focuses on finding undervalued companies in
the micro-cap space. Since 2002, the firm has published an annual
list of recommended stocks as well as comprehensive reports on
select companies throughout the year. LD MICRO concentrates on
finding, researching, and investing in companies that are
overlooked by institutional investors. It is a non-registered
investment advisor. To learn more, please call 408-457-1042 or
visit http://www.ldmicro.com
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and
commercializing our proprietary antimicrobial products that provide
solutions to the health and environmental challenges of pathogen
and hygienic control. Our technology platform is based on patented
stabilized ionic silver, and our initial products contain silver
dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic
antimicrobial agent, which offers 24-hour residual protection and
formulates well with other compounds. As a platform technology, SDC
is distinguished from existing products in the marketplace because
of its superior efficacy, reduced toxicity and the inability of
bacteria to form a resistance to it. PURE is headquartered in El
Cajon, California (San Diego metropolitan area). Additional
information on PURE is available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Forward-looking statements inherently involve risks
and uncertainties that could cause our actual results to differ
materially from the forward-looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to, the Company's cash position and liquidity requirements,
the Company's failure to implement or otherwise achieve the
benefits of its proposed business initiatives and plans, acceptance
of the Company's current and future products and services in the
marketplace, the ability of the Company to develop effective new
products and receive regulatory approvals of such products,
competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the
Securities and Exchange Commission, including our annual
report on Form 10-K filed October 24, 2013. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. By making
these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release.
Contacts: Tom Hemingway Redwood Investment Group 714-978-4425
Email Contact Terri MacInnis Director of IR Bibicoff + MacInnis,
Inc. 818-379-8500 Email Contact Company Contact: Peter C. Wulff CFO
& COO PURE Bioscience, Inc. 619-596-8600 ext.111 Email
Contact
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 6 2024 まで 7 2024
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 7 2023 まで 7 2024